Phosphodiesterase Inhibitors
- 1 Edición - 16 de agosto de 1996
- Última edición
- Editores: Clive Page, Christian Schudt, Gordon Dent, Klaus F. Rabe
- Idioma: Inglés
Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE… Leer más
Descripción
Descripción
Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE isoenzymes were defined which led to the development of the second generation of PDE inhibitors. Currently a variety of these new inhibitors are under test as potential anti-inflammatory drugs. During the past five years, molecular biology has revealed a superfamily of these phosphodiesterase isoenzymes. This book summarizes the present state of knowledge, as well as giving a comprehensive description of the compounds available. It will be invaluable for everyone who wants to choose the most suitable PDE inhibitor for their research or who is dealing with such drugs in a clinical setting.
Puntos claves
Puntos claves
- Utilizes actual testing and research of new PDE inhibitors
- Valuable for researchers and students alike
De interès para
De interès para
Research level pharmacologists, immunologists, and cell biologists; as a reference text in this area for those involved in degree-level teaching. Pharmaceutical companies.
Índice
Índice
K.M. Ferguson and K. Loughney, Identification and Quantification of PDE Isoenzymes and Subtypes by Molecular Biological Methods.
H. Tenor and C. Schudt, Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods.
K.F. Rabe, Effects of Theophylline and Nonselective Xanthine Derivatives on PDE Isoenzymes and Cellular Function.
R.K. Sharma, Interaction of PDE I Inhibitors with Isoenzymes and Cell Functions.
R. Fischmeister, EHNA as an Inhibitor of PDE II.
V.C. Manganiello, PDE II Inhibitors as Therapeutic Agents.
M.A. Giembycz, Interaction of PDE IV Inhibitors with Enzymes and Cell Functions and their Therapeutic Potential.
P.J. Silver, Inhibition of PDE Isoenzymes and Cell Function by Selective PDE V Inhibitors.
J.D. Corbin, Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE V and PDE I.
A. Hatzelmann, Enzymatic and Functional Inhibition of Dual-Selective Inhibitors.
R. Alvarez, Subtype Selectivity, Inhibition of Cell Function and Therapeutic Potential of RS 25344.
J.E. Souness, Characterization of Different States of PDE IV by Rolipram and RP 73401.
T.J. Torphy, Functional Significance of Two Sites for Inhibitors at PDE IV.
Subject Index.
H. Tenor and C. Schudt, Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods.
K.F. Rabe, Effects of Theophylline and Nonselective Xanthine Derivatives on PDE Isoenzymes and Cellular Function.
R.K. Sharma, Interaction of PDE I Inhibitors with Isoenzymes and Cell Functions.
R. Fischmeister, EHNA as an Inhibitor of PDE II.
V.C. Manganiello, PDE II Inhibitors as Therapeutic Agents.
M.A. Giembycz, Interaction of PDE IV Inhibitors with Enzymes and Cell Functions and their Therapeutic Potential.
P.J. Silver, Inhibition of PDE Isoenzymes and Cell Function by Selective PDE V Inhibitors.
J.D. Corbin, Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE V and PDE I.
A. Hatzelmann, Enzymatic and Functional Inhibition of Dual-Selective Inhibitors.
R. Alvarez, Subtype Selectivity, Inhibition of Cell Function and Therapeutic Potential of RS 25344.
J.E. Souness, Characterization of Different States of PDE IV by Rolipram and RP 73401.
T.J. Torphy, Functional Significance of Two Sites for Inhibitors at PDE IV.
Subject Index.
Detalles del producto
Detalles del producto
- Edición: 1
- Última edición
- Publicado: 16 de agosto de 1996
- Idioma: Inglés
Sobre los editores
Sobre los editores
CP
Clive Page
Professor Clive P. Page, BSc PhD OBE HonFBPhS is a Professor of Pharmacology, King’s College London and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease and he has published over 250 scientific papers. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, an AIM listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non Executive Director of and on boards of several companies. He was awarded the Society of Biology President’s Medal in 2012 for an outstanding contribution to the life sciences over the previous year. He is a Fellow of the Royal Society of Biology and an Honorary Fellow and President Elect of the British Pharmacological Society. In 2017, Clive was awarded an OBE for Services to Pharmacology.
Afiliaciones y experiencia
Professor of Pharmacology, King’s College London and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London, UK
CS
Christian Schudt
Afiliaciones y experiencia
Byk Gulden Pharmaceuticals, Konstan, GermanyGD
Gordon Dent
Afiliaciones y experiencia
Kraankenhaus Grobhansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, Grobhansdorf, GermanyKR
Klaus F. Rabe
Afiliaciones y experiencia
Kraankenhaus Grobhansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, Grobhansdorf, GermanyVer libro en ScienceDirect
Ver libro en ScienceDirect
Lee Phosphodiesterase Inhibitors en ScienceDirect